BIOTECH 4BM3 Lecture Notes - Lecture 2: Bioinformatics, Gene Knockout, Biopharmaceutical
15 Jan 2018
School
Department
Course
Professor
Document Summary
Phase iii- the most expensive, sick people, with a dosage increase. Direct link with dosage and efficacy (not with biopharmaceuticals) Wide range of approaches to discovering new drugs: random screening of biological materials, knowledge-based drug identification. Discovery of biopharmaceutical is almost entirely knowledge-based. An understanding at the molecular level of how the body functions in health and disease gives us new strategies for curing/controlling the disease: e. g. insulin for diabetes, growth hormone to treat forms of dwarfism. Our genome contains the raw sequence information of every protein we produce. Less than 1/3 of the genome is transcribed. Only 5% of that rna encodes polypeptides. Previously it was thought that there are 100 k to 120 k polypeptides-encoding genes: nope (its actually 20k to 30k) Ge(cid:374)o(cid:373)i(cid:272) data ha(cid:448)e o(cid:271)(cid:448)ious appli(cid:272)atio(cid:374)s to help ide(cid:374)tify (cid:374)e(cid:449) pote(cid:374)tial (cid:862)(cid:271)iopha(cid:396)(cid:373)a(cid:272)euti(cid:272)al(cid:863) Additionally, this data can provide new potential drug targets: between 3000 and 10000 new protein-based drug targets, not including pathogen targets.
